Skip to content

Examination of clinical effect of green coffee bean extract on healthy subjects.

Examination of clinical effect of green coffee bean extract on healthy subjects. - Examination of clinical effect of green coffee bean extract on healthy subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048584
Enrollment
50
Registered
2022-08-04
Start date
2020-09-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Investigational Product (IP): Neurocaf (Standardized green coffee bean extract), 350 mg capsules Placebo: Maltodextrin, 350 mg capsules

Sponsors

Teikyo Heisei University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Men and women between the ages of 50 and 65. 2. Healthy individuals with a Mini-Mental State Examination (MMSE) score of 24 or higher (because a MMSE score of 23 or lower may be dementia). 3. Those who score 4 points or more on the Simple Fatigue Scale (4-7 points are moderate and 8-10 points are severe). 4. Those who are judged to be right-handed by the H.N. dominant hand test. Unification of the dominant hand is a necessary condition for measuring the amount of hemoglobin (Hb) in the cerebrovascular by NIRS. 5. Those who have subjective symptoms of decreased memory, concentration, and attention (recently feel these symptoms compared to before) or have been pointed out by close relatives that they have decreased memory, concentration, and attention. Person. 6. Those who can attend the research site within the research period. 7. Those who have written consent to participate in this study. 8. Those who have not participated in other experiments within 3 months.

Exclusion criteria

Exclusion criteria: 1. Those who are currently receiving medication due to some kind of breath. 2. Those who currently have a habit of taking or applying drugs. 3. Persons with a history of mental illness or current medical history. 4. Treatment for stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, cerebral contusion Head trauma Those who have experience of hospitalization surgery. 5. Persons with a history of hypertension, dyslipidemia, diabetes, or current medical history. 6. Persons with a history or current medical history of heart failure, renal failure, hepatitis B, hepatitis C. 7. Persons with a history or current medical history of serious disorders such as liver, kidney, heart, lungs, and blood. 8. As a general rule, those who have a history of comorbidities in the digestive system. 9. Persons with a BMI (kg / m2) of 30 or more. 10. Those who drink more than 60g / day on average in terms of alcohol per day. 11. Those who smoke an average of 21 or more cigarettes per day. 12. Those with severe anemia. 13. Those who may have allergic symptoms to the test product, or those who may have serious allergic symptoms to other foods and medicines. 14. Currently, and within the past 3 months, those who have a habit of continuing to take functional foods, health foods, and supplements that appeal to similar effects to the test product, and who plan to take them during the study period. Person. 15. Those who have a habit of continuing to take health foods and supplements containing test-containing ingredients, and who plan to take them during the test period, now and within the past 3 months. 16. Those who may change their lifestyle during the examination period. 17. Those who are currently participating in other human clinical trials, or those who have not been heard for 3 months after participating in other human clinical trials. 18. Others who are judged by the investigator to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
Praimary outcomes is Bourdon' seher Durchstreichte. A Bourdon' seher Durchstreichte is performed before the experiment and after 4 weeks, 8 weeks, and 12 weeks.

Secondary

MeasureTime frame
1.Mini Mental State Examination-Japanese 2.WHOQOL26 3.Uchida Kleperin test 4.Cerebral blood flow in Uchida Kleperin 5.Blood BDNF 6.Blood alpha-synuclein 7.Blood eicosanoyl-5-hydroxytryptamide 8.Blood chlorogenic acid 9.Red blood cells, Hb, hematocrit, platelets, average red blood cell volume, Mean corpuscular hemoglobin Hb amount, mean red blood cell Hb concentration, reticulocyte, white blood cell)

Countries

Japan

Contacts

Public ContactTatsuya Hisajima

Teikyo Heisei University Department of Acupuncture and Moxibustion, Faculty of Health Care

hisajima@thu.ac.jp03-5843-4860

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026